Clinical Trials Browser

OTHER × tislelizumab × Lymphoid × Clear all

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

Hodgkin Disease

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT05977673 2025-12-08

FIL_Tisle-HL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma

NCT07031700 2025-06-22

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Phase 2 Not yet recruiting

Lymphoma, Follicular

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence

NCT05477264 2024-04-03

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Phase 2 Recruiting

Lymphoma

NCT05627115 2023-11-29

RATiFY

Phase 2 Not yet recruiting

Hodgkin Disease

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Unknown

LymphoidOther solid neoplasm

Solid Tumor

NCT05659628 2022-12-21

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Phase 1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04539444 2021-08-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Recurrence

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Phase 2 Unknown

Hodgkin Disease